Experienced in Severe Congenital Neutropenia

Dr. John L. Wagner

Oncology | Hematology
The Metrohealth System
2500 Metrohealth Dr, 
Cleveland, OH 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Experienced in Severe Congenital Neutropenia
The Metrohealth System
2500 Metrohealth Dr, 
Cleveland, OH 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

John Wagner is an Oncologist and a Hematologist in Cleveland, Ohio. Dr. Wagner is rated as an Experienced provider by MediFind in the treatment of Severe Congenital Neutropenia. His top areas of expertise are Acute Myeloid Leukemia (AML), Multiple Myeloma, Myelodysplastic Syndrome (MDS), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Wagner is currently accepting new patients.

His clinical research consists of co-authoring 28 peer reviewed articles and participating in 18 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 1 clinical trial in the study of Severe Congenital Neutropenia.

Specialties
Oncology
Hematology
Licenses
Internal Medicine in VA
Hospital Affiliations
Metrohealth System
University Of Virginia Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
HealthKeepers
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Piedmont
  • HMO
  • POS
Sentara Healthcare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

THE METROHEALTH SYSTEM
2500 Metrohealth Dr, Cleveland, OH 44109
Other Locations
UNIVERSITY OF VIRGINIA PHYSICIANS GROUP
1240 Lee St, Charlottesville, VA 22908

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

18 Clinical Trials

MT2013-31: Allogeneic Hematopoietic Cell Transplantation for Inherited Metabolic Disorders and Severe Osteopetrosis Following Conditioning With Busulfan (Therapeutic Drug Monitoring), Fludarabine +/- ATG
MT2013-31: Allogeneic Hematopoietic Cell Transplantation for Inherited Metabolic Disorders and Severe Osteopetrosis Following Conditioning With Busulfan (Therapeutic Drug Monitoring), Fludarabine +/- ATG
Enrollment Status: Recruiting
Publish Date: August 03, 2025
Intervention Type: Drug, Biological
Study Drugs: Fludarabine, Busulfan, Anti-Thymocyte Globulin, Thiotepa, Rituximab, Alemtuzumab, N-Acetylcysteine, Celecoxib, Vitamin E, Alpha Lipoic Acid
Study Phase: Phase 2
Post Transplant Cyclophosphamide for Unrelated and Related Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies
Post Transplant Cyclophosphamide for Unrelated and Related Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies
Enrollment Status: Completed
Publish Date: December 15, 2025
Intervention Type: Drug, Radiation, Genetic
Study Phase: Phase 2
A Phase II Study of Azacitidine and Sirolimus for the Treatment of High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Refractory to or Not Eligible for Intensive Chemotherapy
A Phase II Study of Azacitidine and Sirolimus for the Treatment of High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Refractory to or Not Eligible for Intensive Chemotherapy
Enrollment Status: Completed
Publish Date: December 10, 2025
Intervention Type: Drug
Study Drugs: Sirolimus, Azacitidine
Study Phase: Phase 2
A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Hematologic Malignancies
A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Hematologic Malignancies
Enrollment Status: Completed
Publish Date: October 30, 2025
Intervention Type: Drug, Radiation, Procedure, Other, Biological
Study Drugs: Fludarabine, Thiotepa, Cyclophosphamide, Tacrolimus, Mycophenolate Mofetil, Allogeneic Lymphocytes
Study Phase: Phase 2
An Open Label Expanded Access Study of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies
An Open Label Expanded Access Study of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies
Enrollment Status: Completed
Publish Date: July 02, 2025
Intervention Type: Biological
Study Phase: Phase 3
A Two-Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Advanced Cutaneous T Cell Lymphoma
A Two-Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Advanced Cutaneous T Cell Lymphoma
Enrollment Status: Withdrawn
Publish Date: May 02, 2025
Intervention Type: Drug, Radiation, Biological, Procedure
Study Phase: Phase 1
Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide for Refractory or Relapsed Aggressive B-cell Lymphomas
Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide for Refractory or Relapsed Aggressive B-cell Lymphomas
Enrollment Status: Completed
Publish Date: April 30, 2025
Intervention Type: Drug, Procedure, Genetic
Study Drugs: Bendamustine, Ofatumumab, Carboplatin, Etoposide
Study Phase: Phase 1/Phase 2
A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies Using One Haploidentical Donor
A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies Using One Haploidentical Donor
Enrollment Status: Completed
Publish Date: April 30, 2025
Intervention Type: Drug, Biological, Procedure, Radiation
Study Phase: Phase 2
A Two Step Approach To Matched-Sibling Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematological Malignancies
A Two Step Approach To Matched-Sibling Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematological Malignancies
Enrollment Status: Completed
Publish Date: April 30, 2025
Intervention Type: Device
Study Phase: Phase 2
A Pilot, Pharmacodynamic Correlate Trial of Sirolimus in Combination With Chemotherapy (Idarubicin, Cytarabine) for the Treatment of Newly Diagnosed Acute Myelogenous Leukemia
A Pilot, Pharmacodynamic Correlate Trial of Sirolimus in Combination With Chemotherapy (Idarubicin, Cytarabine) for the Treatment of Newly Diagnosed Acute Myelogenous Leukemia
Enrollment Status: Completed
Publish Date: April 29, 2025
Intervention Type: Drug
Study Phase: Early Phase 1
A Two Step Approach to Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies
A Two Step Approach to Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies
Enrollment Status: Completed
Publish Date: April 24, 2025
Intervention Type: Drug, Radiation, Other, Biological, Procedure
Study Drugs: Fludarabine, T Cell-Depleted Donor Lymphocyte Infusion, Cyclophosphamide, Tacrolimus, Mycophenolate mofetil
Study Phase: Phase 2
A Multicenter, Randomized, Phase III Registration Trial of Transplantation of NiCord®, Ex Vivo Expanded, UCB-derived, Stem and Progenitor Cells, vs. Unmanipulated UCB for Patients With Hematological Malignancies
A Multicenter, Randomized, Phase III Registration Trial of Transplantation of NiCord®, Ex Vivo Expanded, UCB-derived, Stem and Progenitor Cells, vs. Unmanipulated UCB for Patients With Hematological Malignancies
Enrollment Status: Completed
Publish Date: April 06, 2025
Intervention Type: Drug, Other
Study Drug: Omidubicel
Study Phase: Phase 3
MT2014-10C: Allogeneic Hematopoietic Stem Cell Transplant for Patients With High Risk Hemoglobinopathies and Other Red Cell Transfusion Dependent Disorders
MT2014-10C: Allogeneic Hematopoietic Stem Cell Transplant for Patients With High Risk Hemoglobinopathies and Other Red Cell Transfusion Dependent Disorders
Enrollment Status: Terminated
Publish Date: March 03, 2025
Intervention Type: Drug
Study Phase: Not Applicable
Long Term Follow Up for Patients Who Have Received Allogeneic Stem Cell Transplantation of NiCord®/CordIn™, Umbilical Cord Blood-derived Ex Vivo Expanded Stem and Progenitor Cells
Long Term Follow Up for Patients Who Have Received Allogeneic Stem Cell Transplantation of NiCord®/CordIn™, Umbilical Cord Blood-derived Ex Vivo Expanded Stem and Progenitor Cells
Enrollment Status: Completed
Publish Date: October 23, 2024
Intervention Type: Genetic
A Biomarker Validation Study to Establish Whether Serial Flow Cytometric Measurements Predict Clinical Response to Sirolimus and MEC (Mitoxantrone Etoposide Cytarabine) Treatment in Patients With High-Risk Acute Myelogenous Leukemia
A Biomarker Validation Study to Establish Whether Serial Flow Cytometric Measurements Predict Clinical Response to Sirolimus and MEC (Mitoxantrone Etoposide Cytarabine) Treatment in Patients With High-Risk Acute Myelogenous Leukemia
Enrollment Status: Completed
Publish Date: October 10, 2023
Intervention Type: Drug
Study Drugs: Sirolimus, Mitoxantrone, Etoposide, Cytarabine
Study Phase: Phase 2
A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies
A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies
Enrollment Status: Completed
Publish Date: November 17, 2022
Intervention Type: Radiation, Drug, Biological, Device, Procedure
Study Drugs: Fludarabine, Busulfan, Cyclophosphamide, Tacrolimus, Mycophenolate Mofetil, Donor Lymphocyte Infusion
Study Phase: Phase 2
Allogeneic Stem Cell Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Stem and Progenitor Cells, in Adolescent and Adult Patients With Hematological Malignancies
Allogeneic Stem Cell Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Stem and Progenitor Cells, in Adolescent and Adult Patients With Hematological Malignancies
Enrollment Status: Completed
Publish Date: October 22, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Single-Center, Open Label, Randomized Trial Comparing StemRegenin-1 Expanded Versus Unmanipulated Umbilical Cord Blood Transplantation In Patients With High-Risk Malignancy
Single-Center, Open Label, Randomized Trial Comparing StemRegenin-1 Expanded Versus Unmanipulated Umbilical Cord Blood Transplantation In Patients With High-Risk Malignancy
Enrollment Status: Withdrawn
Publish Date: December 05, 2017
Intervention Type: Biological
Study Phase: Phase 2
View 17 Less Clinical Trials

28 Total Publications

Race-neutral Pulmonary Function Testing in Risk Stratification of Patients Undergoing Autologous Hematopoietic Cell Transplantation.
Race-neutral Pulmonary Function Testing in Risk Stratification of Patients Undergoing Autologous Hematopoietic Cell Transplantation.
Journal: Annals of the American Thoracic Society
Published: October 15, 2025
Similar Doctors
Sophia Balderman
Advanced in Severe Congenital Neutropenia
Dr. Sophia Balderman
Hematology | Oncology
Advanced in Severe Congenital Neutropenia
Dr. Sophia Balderman
Hematology | Oncology

Cleveland Clinic Main Campus

10201 Carnegie Avenue, 
Cleveland, OH 
 (5.1 miles away)
866-223-8100
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Sophia Balderman is a Hematologist and an Oncologist in Cleveland, Ohio. Dr. Balderman is rated as a Distinguished provider by MediFind in the treatment of Severe Congenital Neutropenia. Her top areas of expertise are Myelodysplastic Syndrome (MDS), Aplastic Anemia, Acute Myeloid Leukemia (AML), Bone Marrow Transplant, and Bone Marrow Aspiration.

Advanced in Severe Congenital Neutropenia
Dr. Noman M. Rafique
Hematology Oncology | Hematology | Oncology
Advanced in Severe Congenital Neutropenia
Dr. Noman M. Rafique
Hematology Oncology | Hematology | Oncology

Tri-County Hematology And Oncology Associates Inc

7337 Caritas Cir Nw, Suite 150, 
Massillon, OH 
 (43.2 miles away)
330-478-0001
Languages Spoken:
English, Urdu
See accepted insurances
Accepting New Patients

Noman Rafique is a Hematologist Oncology specialist and a Hematologist in Massillon, Ohio. Dr. Rafique is rated as a Distinguished provider by MediFind in the treatment of Severe Congenital Neutropenia. His top areas of expertise are Choriocarcinoma, Familial Colorectal Cancer, Iron Deficiency Anemia, and Paget Disease of the Breast. Dr. Rafique is currently accepting new patients.

Advanced in Severe Congenital Neutropenia
Dr. Nagaprasad N. Nagajothi
Hematology Oncology | Hematology | Oncology
Advanced in Severe Congenital Neutropenia
Dr. Nagaprasad N. Nagajothi
Hematology Oncology | Hematology | Oncology

Tri-County Hematology And Oncology Associates Inc

7337 Caritas Cir Nw, Suite 150, 
Massillon, OH 
 (43.2 miles away)
330-478-0001
Languages Spoken:
English, Hindi, Tamil, Telugu, Urdu
See accepted insurances
Accepting New Patients

Nagaprasad Nagajothi is a Hematologist Oncology specialist and a Hematologist in Massillon, Ohio. Dr. Nagajothi is rated as a Distinguished provider by MediFind in the treatment of Severe Congenital Neutropenia. His top areas of expertise are Lung Cancer, Large-Cell Immunoblastic Lymphoma, Pleuropulmonary Blastoma, and Familial Colorectal Cancer. Dr. Nagajothi is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Wagner's expertise for a condition
ConditionClose
    View All 11 Advanced Conditions
    View All 72 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile